Los Angeles Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2024
Q3 | – | Sell |
-132,606
| Closed | -$743K | – | 1328 |
|
2024
Q2 | $743K | Sell |
132,606
-59,126
| -31% | -$331K | ﹤0.01% | 748 |
|
2024
Q1 | $1M | Buy |
191,732
+100,470
| +110% | +$526K | ﹤0.01% | 687 |
|
2023
Q4 | $477K | Buy |
91,262
+36,982
| +68% | +$193K | ﹤0.01% | 885 |
|
2023
Q3 | $856K | Sell |
54,280
-15,404
| -22% | -$243K | ﹤0.01% | 689 |
|
2023
Q2 | $1.35M | Sell |
69,684
-4,931
| -7% | -$95.9K | 0.01% | 582 |
|
2023
Q1 | $2.12M | Buy |
74,615
+32,339
| +76% | +$917K | 0.01% | 485 |
|
2022
Q4 | $1.24M | Buy |
+42,276
| New | +$1.24M | 0.01% | 645 |
|
2022
Q3 | – | Sell |
-34,358
| Closed | -$1.53M | – | 1408 |
|
2022
Q2 | $1.53M | Sell |
34,358
-9,036
| -21% | -$402K | 0.01% | 597 |
|
2022
Q1 | $2.15M | Buy |
43,394
+4,476
| +12% | +$222K | 0.01% | 509 |
|
2021
Q4 | $1.98M | Sell |
38,918
-21
| -0.1% | -$1.07K | 0.01% | 517 |
|
2021
Q3 | $2.17M | Sell |
38,939
-3,770
| -9% | -$210K | 0.01% | 515 |
|
2021
Q2 | $1.83M | Buy |
42,709
+25,050
| +142% | +$1.07M | 0.01% | 609 |
|
2021
Q1 | $737K | Sell |
17,659
-2,115
| -11% | -$88.3K | ﹤0.01% | 1048 |
|
2020
Q4 | $921K | Sell |
19,774
-18,375
| -48% | -$856K | ﹤0.01% | 976 |
|
2020
Q3 | $1.62M | Sell |
38,149
-7,637
| -17% | -$325K | 0.01% | 635 |
|
2020
Q2 | $2.2M | Buy |
45,786
+13,681
| +43% | +$656K | 0.01% | 591 |
|
2020
Q1 | $1.48M | Buy |
32,105
+10,910
| +51% | +$502K | 0.01% | 615 |
|
2019
Q4 | $1.27M | Hold |
21,195
| – | – | 0.01% | 765 |
|
2019
Q3 | $1.2M | Buy |
21,195
+6,530
| +45% | +$369K | 0.01% | 764 |
|
2019
Q2 | $817K | Hold |
14,665
| – | – | ﹤0.01% | 904 |
|
2019
Q1 | $740K | Hold |
14,665
| – | – | ﹤0.01% | 962 |
|
2018
Q4 | $591K | Buy |
14,665
+2,115
| +17% | +$85.2K | ﹤0.01% | 916 |
|
2018
Q3 | $870K | Buy |
+12,550
| New | +$870K | ﹤0.01% | 918 |
|